The hypoxia-activated prodrug evofosfamide in combination with multiple regimens of radiotherapy

The promising treatment combination of ionizing radiation (IR) with a hypoxia-activated prodrug (HAP) is based on biological cooperation. Here we investigated the hypoxia-activated prodrug evofosfamide in combination with different treatment regimens of IR against lung A549- and head&neck UT-SCC...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncotarget
Auteurs principaux: Nytko, Katarzyna J., Grgic, Ivo, Bender, Sabine, Ott, Janosch, Guckenberger, Matthias, Riesterer, Oliver, Pruschy, Martin
Format: Artigo
Langue:Inglês
Publié: Impact Journals LLC 2017
Sujets:
Research Paper
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5410338/
https://ncbi.nlm.nih.gov/pubmed/28423594
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.15784
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires